



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,

Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 18th January, 2020

To:

The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

Security Code: 532815

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: U.S. FDA completes inspection of Kandivalasa, Vizianagaram, Andhra Pradesh API Facility.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at our Kandivalasa, Vizianagaram, Andhra Pradesh API manufacturing facility from 13th January 2020 to 17th January, 2020.


The inspection ended with Two observations which are procedural in nature and correctable which company believes are minor in nature and no data integrity issues were observed in the inspection.

The Company is committed to meeting the highest quality standards and are further committed to full compliance with CGMP regulations at all our manufacturing facilities. The Kandivalasa Unit is one of our Active Pharmaceutical Ingredients (API) manufacturing facility, and this was the third U.S. FDA inspection. The Company is confident to address the observations raised by the agency satisfactorily and will submit our comprehensive response within the stipulated timeline.

This is for your information and records.

Thanking you

Yours Faithfully
For SMS Pharmaceuticals Limited


Ramesh Babu Potluri
Chairman and Managing Director